Targeted Partnerships Opportunity to partner with pharma/biotech for funded collaborations to develop and apply SnapPath and PathMAP as predictive biomarkers to guide targeted therapies for solid tumors.

Live PD Readouts Proven capability to measure pharmacodynamic responses in live tumor cells across MAPK, JAK/STAT, and PI3K pathways, providing PD readouts that can support dose selection, patient stratification, and biomarker-driven trials.

Early Access Available Research Use capabilities for preclinical tumorgraft studies and early clinical assessments offer a low-friction route to incorporate functional signaling profiling into early drug development programs.

Leadership Growth Recent leadership promotions indicating strategic emphasis on operations and science, suggesting readiness to scale collaborations and manage complex pharma partnerships.

Strategic Locale Location in Rockville, MD places BioMarker Strategies in proximity to biotech networks and potential US government, academic, and pharma collaborators, supporting regional BD outreach.